Intelligence Feed event · Policy · 2026-10-01

    Theriva Biologics VIRAGE Phase 2b Data Published in Nature Medicine

    Question

    Theriva Biologics VIRAGE Phase 2b Data Published in Nature Medicine

    Direct answer

    Theriva Biologics announced the formal peer-reviewed publication of its Phase 2b VIRAGE clinical trial in Nature Medicine. The trial evaluated VCN-01, an oncolytic adenovirus (zabilugene almadenorepvec), administered alongside standard-of-care chemotherapy. The published data demonstrated improvements across overall survival, progression-free survival, and response duration in patients with metastatic pancreatic ductal adenocarcinoma, providing clinical validation for subsequent pivotal development stages.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Theriva Biologics VIRAGE Phase 2b Data Published in Nature Medicine”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/theriva-biologics-virage-phase-2b-data-published-in-nature-medicine-d20f9a

    POLICY
    Theriva Biologics VIRAGE Phase 2b Data Published in Nature Medicine
    Theriva Biologics announced the formal peer-reviewed publication of its Phase 2b VIRAGE clinical trial in Nature Medicine. The trial evaluated VCN-01, an oncolytic adenovirus (zabilugene almadenorepvec), administered alongside standard-of-care chemotherapy. The published data demonstrated improvements across overall survival, progression-free survival, and response duration in patients with metastatic pancreatic ductal adenocarcinoma, providing clinical validation for subsequent pivotal development stages.
    TOVX
    Impact
    66
    OCT 1
    SIG
    85%
    TOVX
    Theriva Biologics VIRAGE Phase 2b Data Published in Nature Medicine
    Theriva Biologics announced the formal peer-reviewed publication of its Phase 2b VIRAGE clinical trial in Nature Medicine. The trial evaluated VCN-01, an oncolytic adenovirus (zabilugene almadenorepvec), administered alongside standard-of-care chemotherapy. The published data demonstrated improvements across overall survival, progression-free survival, and response duration in patients with metastatic pancreatic ductal adenocarcinoma, providing clinical validation for subsequent pivotal development stages.
    → Peer-reviewed overall survival improvement advances VCN-01 toward Phase 3 pancreatic oncology pivotal trials.
    Impact
    Theriva Biologics announced the formal peer-reviewed publication of its Phase 2b VIRAGE clinical trial in Nature Medicine. The trial evaluated VCN-01, an oncolytic adenovirus (zabilugene almadenorepvec), administered alongside standard-of-care chemotherapy. The published data demonstrated improvements across overall survival, progression-free survival, and response duration in patients with metastatic pancreatic ductal adenocarcinoma, providing clinical validation for subsequent pivotal development stages.
    Affected
    TOVX
    Transmission
    Peer-reviewed overall survival improvement advances VCN-01 toward Phase 3 pancreatic oncology pivotal trials.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TOVXclinical pipeline validationUp1-5dNature Medicine publication validates Phase 2b overall survival improvements in metastatic pancreatic cancer.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month